Avent J, Vervaert C, Seigler H F
J Surg Oncol. 1979;12(1):87-96. doi: 10.1002/jso.2930120111.
Conflicts amongst reports concerning the efficacy of both nonspecific and specific attempts at immunotherapy may be ascribed to different animal models utilizing tumors of different immunogenicity. We have selected the B16 mouse melanoma model as the example of a spontaneously occurring neoplasm that is histocompatible with the host and does have tumor-associated antigens. Attempts to alter tumor growth or survival with nonspecific active immunotherapy as well as with specific active immunotherapy were not successful. Nonspecific active pre-immunization failed to alter tumor take or growth. Specific active immunotherapy both with and without adjuvant did decrease tumor take and prolong host survival. The effects were increasingly documented at lower tumor cell inoculums and became less apparent with increase in the tumor cell challenge.
关于非特异性和特异性免疫治疗尝试的疗效报告之间的冲突，可能归因于使用具有不同免疫原性肿瘤的不同动物模型。我们选择了B16小鼠黑色素瘤模型作为自发发生肿瘤的例子，该肿瘤与宿主组织相容性良好且确实具有肿瘤相关抗原。使用非特异性主动免疫疗法以及特异性主动免疫疗法来改变肿瘤生长或存活的尝试均未成功。非特异性主动预免疫未能改变肿瘤的接种或生长。无论有无佐剂，特异性主动免疫疗法确实都减少了肿瘤接种并延长了宿主存活时间。在较低肿瘤细胞接种量时，这些效果越来越明显，而随着肿瘤细胞攻击量的增加则变得不那么明显。
